| Erdafitinib for the treatment of metastatic bladder cancer K Montazeri, J Bellmunt Expert review of clinical pharmacology 13 (1), 1-6, 2020 | 89 | 2020 |
| Urinalysis in acute care of adults: pitfalls in testing and interpreting results DJ Pallin, C Ronan, K Montazeri, K Wai, A Gold, S Parmar, JD Schuur Open forum infectious diseases 1 (1), ofu019, 2014 | 74 | 2014 |
| ABCDE steps to prevent heart disease in breast cancer survivors K Montazeri, C Unitt, JAM Foody, JR Harris, AH Partridge, J Moslehi Circulation 130 (18), e157-e159, 2014 | 40 | 2014 |
| Breast cancer chemotherapy and your heart C Unitt, K Montazeri, S Tolaney, J Moslehi Circulation 129 (25), e680-e682, 2014 | 21 | 2014 |
| Tebentafusp in the treatment of metastatic uveal melanoma: Patient selection and special considerations K Montazeri, V Pattanayak, RJ Sullivan Drug Design, Development and Therapy, 333-339, 2023 | 12 | 2023 |
| Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive … CI Herold, L Trippa, T Li, K Do, A Bardia, L Anderson, K Montazeri, ... Cancer Research 80 (4_Supplement), P3-14-03-P3-14-03, 2020 | 7 | 2020 |
| Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need K Montazeri, G Sonpavde Expert Review of Anticancer Therapy 21 (3), 299-313, 2021 | 5 | 2021 |
| 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial SP Patel, R Carvajal, K Montazeri, S Reddy, J Lutzky, SA Khan, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | 3 | 2023 |
| An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as … K Montazeri, G Dranitsaris, JD Thomas, C Curran, MA Preston, GS Steele, ... Urologic Oncology: Seminars and Original Investigations 39 (12), 834. e1-834. e7, 2021 | 3 | 2021 |
| 832P treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+ IPI) in HLA-A2* 02: 01 patients (pts) with metastatic uveal melanoma (mUM) F Dimitriou, JC Hassel, M Orloff, I Hughes, E Kapiteijn, I Mehmi, ... Annals of Oncology 33, S929, 2022 | 2 | 2022 |
| A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer … C Herold, L Trippa, T Li, K Do, A Bardia, L Anderson, K Montazeri, ... San Antonio Breast Cancer Symposium, 2019 | 2 | 2019 |
| Análisis de orina en emergencias DJ Pallin, C Ronan, K Montazeri, K Wai, A Gold, S Parmar, S Fuente Errores de interpretación y tratamientos innecesarios. Artículos, 2014 | 2 | 2014 |
| Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis M Wang, KL Reynolds, K Montazeri, EA Schaefer, RJ Sullivan, M Dougan Clinical Gastroenterology and Hepatology 22 (7), 1539-1541. e2, 2024 | 1 | 2024 |
| 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma S Patel, M Mckean, S Piperno-Neumann, AN Shoushtari, ... Annals of Oncology 34, S677-S678, 2023 | 1 | 2023 |
| Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma D Suwajanakorn, AM Lane, AK Go, CD Hartley, M Oxenreiter, F Wu, ... Melanoma Research, 10.1097, 2024 | | 2024 |
| Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever AM Mohareb, J Kang, K Montazeri, SG Shroff New England Journal of Medicine 390 (3), 255-265, 2024 | | 2024 |
| Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma T Sato, K Montazeri, ES Gragoudas, AM Lane, MB Aronow, JV Cohen, ... JCO Precision Oncology 8, e2300368, 2024 | | 2024 |
| 133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors D Davar, JG Knecht, AL Vandross, CA Perez, DM Miller, J Powderly, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal … K Montazeri, D Davar, CL Haymaker, R Sheth, J Kuban, J Weintraub, ... Journal of Clinical Oncology 41 (16_suppl), 2521-2521, 2023 | | 2023 |
| PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure-enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD … SP Patel, C Haymaker, RA Sheth, JD Kuban, J Weintraub, ... Cancer Research 83 (7_Supplement), 5881-5881, 2023 | | 2023 |
